Pontchartrain Cancer Center | Covington, LA

Research site

(Unclaimed)

Location

120 Lakeview Circle, Covington, Louisiana, United States of America

Site insights

Top conditions

Top treatments

Docetaxel

Cyclophosphamide

Azacitidine

Pracinostat

Tislelizumab

Pegfilgrastim

Bevacizumab

Vinflunine

Erdafitinib

Serplulimab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 22 total trials

A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera (VERIFY)

The study is designed to evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and...

Active, not recruiting

Polycythemia Vera

Drug: Placebo

Drug: Rusfertide

Locations recently updated

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania)

This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have rec...

Enrolling

Breast Cancer

Drug: Trastuzumab Emtansine

Drug: Placebo

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the phy...

Enrolling

Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

Drug: Fulvestrant

Drug: Dexamethasone Mouth Rinse

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis (REFINE)

This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants...

Active, not recruiting

Myelofibrosis (MF)

Drug: Navitoclax

Drug: Ruxolitinib

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus Tislelizumab when administered in combination with bevacizumab plus...

Enrolling

Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Drug: 5-Fluorouracil

Drug: Tislelizumab

A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer (DisTinGuish)

A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Pati...

Active, not recruiting

Gastric Cancer

GastroEsophageal Cancer

Drug: Tislelizumab 200mg

Drug: DKN-01 400mg

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations (THOR)

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer...

Active, not recruiting

Urothelial Cancer

Drug: Erdafitinib

Drug: Docetaxel

A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors (Tamarack)

Study CP-MGC018-03 is an open-label, two-part, Phase 2 study. Part 1 of the study will enroll participants with metastatic castration-resistant prost...

Active, not recruiting

Anal Cancer

Small-cell Lung Cancer

Biological: vobramitamab duocarmazine

Biological: vobramitamab duocarmazine 2.7 mg (Arm B)

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of Serplulimab + chemothe...

Enrolling

Limited-Stage Small Cell Lung Cancer

Drug: carboplatin/cisplatin-etoposide

Drug: Placebo

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R ver...

Enrolling

Myelodysplastic Syndromes

Biological: Epoetin Alfa

Biological: Luspatercept

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in...

Enrolling

Extensive Stage Small Cell Lung Cancer

Drug: Serplulimab + chemotherapy (carboplatin-etoposide)

Drug: Atezolizumab + chemotherapy (carboplatin-etoposide)